Almirall starts human trials of skin treatment

Spanish dermatology group Almirall has administered the first dose in a phase I trial of a new potential treatment for autoimmune skin diseases.

Photo: Almirall / PR

Almirall has started a phase I trial of a potential treatment for autoimmune skin diseases, the Spanish firm reports in a press release.

The company licensed the IL-1RAP antagonist treatment, which is now called ALM27134 instead of its previous name, ISB 880, from French-American Ichnos Sciences.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs